BioCryst Pharmaceuticals, Inc. (BCRX) is a commercial-stage biopharmaceutical company, not an ETF. Its flagship product is ORLADEYO (berotralstat), an oral, once-daily preventive therapy for hereditary angioedema.
The average analyst price target near $20.50 is built from roughly a dozen published targets spanning approximately $9 to $32. At the high end, firms such as H.C. Wainwright ($32) and TD Cowen ($30) emphasize ORLADEYO's durability and the long-term pipeline. Mid-range targets from Cantor Fitzgerald ($29), Citizens JMP ($28), Wedbush ($17), Evercore ISI ($17), and Bank of America Securities ($15) reflect a constructive but more tempered view. The cautious end includes J.P. Morgan ($13), RBC Capital ($11), and Barclays near $9, which stress competitive and balance-sheet risk. No single figure is a guarantee; the wide range signals genuine disagreement about the company's path. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Shares closed near $7.61 in mid-November 2026, toward the lower end of a 52-week range of roughly $6.23 to $11.22, with a market capitalization around $2 billion. A move to $20 implies an upside of about 163%, which is a very large move for a company of this size and would likely require both sustained commercial execution and a meaningful re-rating of the stock.
The company reported third-quarter 2026 revenue of $180.3 million and GAAP net income of $37.9 million, with ORLADEYO revenue reaching $174.8 million. Full-year 2026 total revenue guidance was raised to $715 million to $730 million, though much of the increase came from lower-margin licensing and government-order sources rather than the core HAE franchise. The path toward $20 would depend on durable ORLADEYO growth, pipeline progress, and improving profitability rather than a single quarterly result.
From a technical standpoint, the stock has traded between roughly $6.23 and $11.22 over the past year. The $6.20-to-$6.50 zone has acted as a notable support area, while $10 to $11 represents a well-defined resistance level. A sustained advance toward the $20 target would first require a decisive break above the $11 area, which currently sits well above the prevailing price and marks the upper boundary of the recent range.
Analyst price targets generally reflect a research horizon of approximately 12 months, though individual analysts may use different assumptions and timeframes. Investors should watch quarterly ORLADEYO sales trends and whether the inventory-driven strength repeats, updates to full-year guidance, progress on navenibart and other pipeline programs, the integration of Astria, any further government contracts, and shifts in the competitive HAE landscape. Balance-sheet developments and analyst target revisions will also matter, given how widely views currently diverge. From what I see, this is important because the outcome hinges on consistent execution over multiple quarters.
For traders tracking names like BCRX, Tickeron's AI Daily Buy/Sell Signals offer an additional analytical layer. The system uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. This can help traders discover new opportunities, keep an eye on existing positions, and spot shifting trends more efficiently than manual review. I find it useful to pair these signals with my own research and the analyst framework when evaluating any position.
The $20 central target is derived from the average of current analyst price targets, not from an official published consensus figure, and it sits roughly 163% above the recent share price of about $7.61. The wide target range—from roughly $9 to $32—underscores how divided analysts are on BioCryst's outlook. Bullish cases rest on ORLADEYO's commercial durability and the Astria pipeline, while cautious views emphasize competition, balance-sheet strain, and execution risk. Reaching $20 would represent a very large move requiring both sustained fundamentals and a broader re-rating. It is a plausible scenario embedded in analyst modeling, but it is far from assured, and the outcome will depend heavily on commercial execution and competitive developments over the coming quarters.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BCRX advanced for three days, in 202 of 263 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Momentum Indicator moved below the 0 level on November 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BCRX as a result. In 73 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for BCRX turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 46 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
The 50-day moving average for BCRX moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
BCRX broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BCRX entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.326) is normal, around the industry mean (6.379). P/E Ratio (-5.696) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (2.097) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. BCRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of small molecule pharmaceuticals
Industry PharmaceuticalsGeneric